PhD Scientific Days 2026

Poster Session 2.G - Pharmaceutical Sciences and Health Technologies

Development of a Low-Volume Discriminatory In Vitro Dissolution Method for Ocular Drug Delivery Systems Integrated with Pharmacokinetic Modeling: Proof-of-Concept Using Levofloxacin Nanofiber Inserts

Előadó neve

Dr. Abboud, Houssam

Neptune code

IWD5AR

Előadó munkahelye

University Pharmacy, Department of Pharmacy Administration

Előadó telefonszáma

704027555

Előadó e-mail címe

houssam.abboud@phd.semmelweis.hu

Az előadás címe

Development of a Low-Volume Discriminatory In Vitro Dissolution Method for Ocular Drug Delivery Systems Integrated with Pharmacokinetic Modeling: Proof-of-Concept Using Levofloxacin Nanofiber Inserts

Szerző(k) neve és munkahelye

Houssam Abboud¹, Romana Zelkó¹, Adrienn Nochta-Kazsoki¹

1: University Pharmacy, Department of Pharmacy Administration

Bemutatás módja

Poszter

Szekció

Poster Session 2.G - Pharmaceutical Sciences and Health Technologies

Language of the presentation

English

Preferred session

Pharmaceutical Sciences and Health Technologies

Összefoglaló szövege

Introduction: A major limitation in evaluating drug release from ocular formulations is the reliance on large dissolution media (typically 20–100 mL) during in vitro testing. These conditions differ substantially from the physiological tear volume (7–30 µL) and often fail to capture viscosity-dependent mechanisms governing drug release from systems such as inserts, in-situ gels, viscous eye drops, and polymeric formulations, where dilution may mask formulation-dependent release behavior. This mismatch reduces the discriminatory power of early screening methods.
Aims: To develop a practical small-volume (2 mL) dissolution screening method with improved discriminatory capacity for ocular formulations and demonstrate its relevance using a levofloxacin (LEVO)-loaded nanofibrous insert as a model system.
Methods: LEVO-loaded nanofibrous inserts from our previous work were used as a model formulation. A custom 2 mL dissolution device was developed. Drug release was compared with conventional 40 mL conditions using Weibull kinetic modeling and model-independent comparison factors (f₁, f₂). Pharmacokinetic simulations compared once- and twice-daily insert administration with eye drops given every 2 h. Simulations incorporated release kinetics, ocular volume constraints, clearance assumptions based on literature tear half-life values, and pathogen-specific MIC/MBC thresholds to enable clinically relevant comparison.
Results: The 2 mL setup showed slower diffusion-controlled release (d = 0.915) compared with rapid release in 40 mL (d = 0.159), with f₁ and f₂ confirming significant profile differences. The smaller volume preserved viscosity-related gelation effects masked under sink conditions. Pharmacokinetic modeling showed twice-daily inserts maintained LEVO concentrations above MIC and MBC levels longer than eye drops.
Conclusion: The 2 mL dissolution approach represents a practical and discriminatory in vitro screening platform applicable to diverse ocular formulations including inserts, in-situ gels, and other sustained-release systems. Although demonstrated with nanofibers, the method is formulation-independent and may serve as a general early screening tool to improve formulation selection and predict in vivo performance.
Funding: Supported by the Semmelweis 250+ and the EKÖP-2024-00004 University Research Scholarship Program (NRDI Fund, Hungary).

University

Semmelweis University

Supervisor

Dr. Adrienn Nochta-Kazsoki

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies after complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

8020

Start

18:00

End

18:03